slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 75,451-75,480
Pages 3,225
Rows per page 30
Component
75,451-75,480 of 96,741
132
The slide uses a line chart to demonstrate that the fasting glucose values are identical to a previous study (Miller et al 2024), implying the new HbA1c claims are fabricated.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
133
The slide highlights that GH induces insulin resistance while DCCR blocks insulin release, creating a synergistic risk for hyperglycemia.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
136
The slide uses a 'two-hit' metaphor to describe the synergistic risk of the two medications.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
138
The slide uses a list of 6 risk factors to build a medical case for why the drug's side effects are particularly dangerous for this specific patient group.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
139
The slide uses a combination of a table excerpt and a text excerpt to highlight a specific reporting discrepancy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
140
Uses red boxes and arrows to visually connect the contradictory data points.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
141
The red box highlights the 30.4% peripheral edema rate. The text argues that the conflation of data between the P3 study and the extension study is an intentional attempt to hide worsening safety profiles.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
142
The slide uses medical definitions to frame the clinical trial results as evidence of adverse effects (edema) related to the drug DCCR.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
143
The slide uses a causal chain structure to explain the side effect.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
144
The slide uses a medical illustration to show the impact of fluid retention on heart chambers (diastolic vs systolic).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
146
The slide uses a technical explanation of DEXA limitations to undermine the company's reported clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
147
The slide uses a table to highlight inconsistencies in clinical trial data to suggest misclassification of medical outcomes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
148
The slide uses a table to map shared mechanisms of edema between GH and Diazoxide, and a second table to highlight the high prevalence of GH use in the P3 study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
149
The slide uses red boxes to highlight specific text in the protocol that contradicts the lack of reporting in the final study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
150
The slide uses a direct quote from a physician to undermine the company's marketing claims.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
153
The slide uses a combination of medical argumentation and cited research conclusions to highlight the risks of a specific drug regimen.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
154
The slide uses direct quotes from pediatric endocrinologists to highlight safety concerns, specifically referencing the drug's potential to exacerbate existing cardiac risks in PWS patients.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
155
The slide uses Q&A transcripts to expose the risks associated with the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
157
Uses social media follower counts as a proxy for community size to highlight the lack of engagement with the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
158
The slide highlights the discrepancy between the expected community interest and the actual low membership/activity numbers.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
159
The slide uses a specific Facebook post as a case study to contradict the product's efficacy claims.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
160
The slide uses screenshots of Facebook comments to build a case against the drug's efficacy and safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
161
The slide uses anecdotal evidence from Facebook groups to highlight negative side effects (hyperphagia, behavioral changes) associated with the drug VYKAT.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
162
The slide uses screenshots of Facebook posts to provide qualitative evidence of patient dissatisfaction and safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
163
The slide uses direct quotes from Facebook groups to build a case against the drug's efficacy/safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
164
The slide uses screenshots of Facebook comments to illustrate the divide between frustrated participants and those defending the study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
165
The slide uses social media screenshots to establish a pattern of adverse events.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
166
The slide uses anecdotal evidence from Facebook discussion groups to highlight potential adverse drug reactions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
167
The slide uses screenshots of Facebook group posts to provide anecdotal evidence of drug side effects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
168
The slide uses patient testimonials to contradict the safety profile of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit